Lei Jianping on April 25
The IPO of Shanghai Jiangen Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Jiangen Pharmaceutical") was terminated a few days ago, and Jiangen Pharmaceutical was preparing to be listed on the Science and Technology Innovation Board.
Jiangeng Pharmaceutical originally planned to raise 1.023 billion yuan, of which 350 million yuan was used for organ transplantation innovation and R&D platform projects, 175 million yuan for kidney transplant equipment localization and upgrading R&D projects, 207 million yuan for liver transplantation equipment and in vitro diagnostic reagent product registration and promotion projects in the field of transplantation, 51.67 million yuan for information system construction projects, and 240 million yuan for supplementing working capital.
The annual revenue is 480 million
The company's product line includes equipment for organ preservation, transportation, evaluation and repair of intraoperative organs, transplantation medical consumables, in vitro diagnostic reagents, etc., covering the whole stage of preoperative evaluation, perioperative treatment and long-term postoperative management of organ transplantation.
According to the prospectus, Jiangen Pharmaceutical's revenue in 2019, 2020 and 2021 will be 397 million yuan, 420 million yuan and 480 million yuan respectively, the net profit will be 127 million yuan, 72.7539 million yuan and 63.2198 million yuan respectively, and the net profit after deducting non-profits will be 15.4934 million yuan, 29.5664 million yuan and 71.958 million yuan respectively.
In the first quarter of 2022, Jiangen Pharmaceutical's revenue was 114 million yuan, with a net profit of 12.1475 million yuan, and a net profit of 12.276 million yuan after deducting non-profits.
During the reporting period, the book value of the company's accounts receivable was 100 million yuan, 95.03 million yuan, 92.83 million yuan and 107 million yuan respectively, accounting for 28.99%, 21.77%, 22.60% and 24.32% of current assets respectively.
Sunshine Life and Legend are shareholders
Before the IPO, Wu Yunlin held 19,729,987 shares of the company, accounting for 28.02% of the company's total share capital, and Shanghai Jingsheng Investment Enterprise (Limited Partnership), a shareholding platform controlled by Wu Yunlin, held 3,157,330 shares of the company, accounting for 4.48% of the company's total share capital, so Wu Yunlin could directly and indirectly control a total of 32.51% of the company's shares and was the controlling shareholder and actual controller of the company.
Wu Yunlin, born in October 1971, holds a bachelor's degree from Shanghai University of Traditional Chinese Medicine, and has served as a surgeon in Shanghai Longhua Hospital and a regional manager of Hong Kong Fujisawa Pharmaceutical Co., Ltd., the chairman and general manager of Jiangen Co., Ltd. from 2004 to November 2014, and the chairman and general manager of the company since December 2014.
Before the IPO, Sunshine Life held 23.7832% of the shares, Legend Chengye held 6.1292%, Nanjing Xinjun held 5.8425%, Jingsheng Investment held 4.4847%, Junlian Yikang held 3.0712%, Liu Yunjiang held 2.7629%, Borun Investment held 2.6568%, Jiang Jian held 1.9113%, Junlian Jiayun held 1.8372%, Puhua Investment held 1.7964%, and Xinjun Venture Capital held 1.7147%;
Jintou Huijian holds 1.2248% of the shares, Borun New Third Board and Hangzhou Boshui hold 1.107% of the shares, Jiangxi Xinhe holds 1.0207% of the shares, Jiating Investment holds 0.8996% of the shares, Chen Jianqin holds 0.8651% of the shares, Gaoke Venture Capital and Shanghai Science and Technology Venture Capital hold 0.8165% of the shares, Wu Fengbo holds 0.6813% of the shares, Qingdao Tongzhou holds 0.6416% of the shares, Ningbo Rongsong holds 0.6124% of the shares, and Xu Guodong holds 0.6063% of the shares.
Jingsheng Investment is a shareholding platform controlled by Wu Yunlin, who holds the partnership share of Jingsheng Investment, the shareholder, and serves as its executive partner; Wu Yunlin's spouse Wu Xiuping holds the partnership share of Jingsheng Investment; and Wu Yunlin and Liu Yunjiang are brothers.
Legend Chengye, Legend Yikang and Legend Jiayun are all controlled by Legend Capital Management Co., Ltd. The executive partners of Borun Investment, Borun New Third Board, Hangzhou Boshui and Tonglu Kangrun are all Shanghai Borun.
Nanjing Xinjun, Xinjun Venture Capital, Gaoke Venture Capital and Nanjing Yujun are all controlled by Nanjing Gaoke Xinjun Investment Management Co., Ltd. or its major shareholder Qin Yangwen.
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.